Long-term clinical and tissue data collection for people with thoracic cancers

Prospective Data Collection Initiative on Thoracic Malignancies - a Prospective Observational Cohort Study

This project will collect medical records, imaging, quality-of-life information, and tissue/blood samples over time from adults with thoracic cancers to try to find factors that predict outcomes.

Quick facts

• Study type: Observational
• Enrollment: 12000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Dutch Society of Physicians for Pulmonology and Tuberculosis (other)
• Locations: 10 sites (Ede, Gelderland and 9 other locations)
• Trial ID: NCT06996249 on ClinicalTrials.gov

What this trial studies

This is a prospective, observational Dutch cohort enrolling adults with confirmed or strongly suspected thoracic malignancies and following them from diagnosis until death. Clinical data, imaging, pathology, treatment details, adverse events, and patient-reported outcomes will be collected longitudinally, with optional consent for biobanking of blood, tumor tissue, and imaging for research and AI use. The cohort is designed to serve as an infrastructure for future embedded interventions using a Trials within Cohorts (TwiCs) approach, with separate consent required for non-standard treatments. Recruitment occurs across multiple participating hospitals in the Netherlands and participation requires informed consent.

Who should consider this trial

Good fit: Adults (≥18) with histo/cytopathological proof or a strong clinical suspicion of a thoracic malignancy who can provide informed consent and receive care at a participating center.

Not a fit: People who cannot provide informed consent or who expect direct therapeutic benefit from participation are unlikely to gain direct clinical benefit because the project is observational and does not change standard treatment.

Why it matters

Potential benefit: If successful, the cohort could help doctors predict recurrence and survival more accurately and tailor care to individual patients.

How similar studies have performed: Large prospective cancer cohorts and biobanks have previously identified prognostic biomarkers and TwiCs has been used successfully, so this approach builds on established methods.

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 years;
* Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board);
* Informed consent for longitudinal observational data collection;

Exclusion Criteria:

* Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator.
* Inability to provide a written or electronic informed consent.

Where this trial is running

Ede, Gelderland and 9 other locations

• Ziekenhuis Gelderse Vallei — Ede, Gelderland, Netherlands (RECRUITING)
• Máxima MC — Eindhoven, North Brabant, Netherlands (RECRUITING)
• Tergooi MC — Hilversum, Utrecht, Netherlands (RECRUITING)
• Diakonessenhuis — Utrecht, Utrecht, Netherlands (RECRUITING)
• Meander MC — Amersfoort, Netherlands (RECRUITING)
• MUMC+ — Maastricht, Netherlands (RECRUITING)
• CWZ (Canisius Wilhelmina Ziekenhuis) — Nijmegen, Netherlands (RECRUITING)
• Erasmus MC — Rotterdam, Netherlands (RECRUITING)
• Zuyderland — Sittard, Netherlands (RECRUITING)
• UMC Utrecht — Utrecht, Netherlands (RECRUITING)

Study contacts

• Principal investigator: W.K. de Jong, Dr. — UMC Utrecht
• Study coordinator: F.T.A. van der Velde

Conditions: Lung Cancer, Thoracic Cancer, Lung Cancer, Nonsmall Cell, Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Lung Cancer, Thymus Cancer, Mesothelioma